A brain aneurysm is a weak, bulging spot on the wall of an artery. Our unique portfolio for ruptured and unruptured aneurysms is backed by numerous clinical studies and independent research for great performance and versatility.
Find out more
A stroke is a permanent injury to the brain caused by blockage of blood flow depriving the brain tissue of oxygen and nutrients. This diverse portfolio includes carotid stents, aspiration catheters, and mechanical thrombectomy products.
Find out more
Malformations are an abnormal tangle of blood vessels that cause arteries to shunt directly into veins, the blood flow never slows down enough to provide oxygen and nutrients. We took a novel approach by designing a ready-to-use liquid embolic device for malformations.
Find out more
MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.
The prestigious award is based entirely on what current employees say about their experience working at MicroVention. This year, 80% of employees said it’s a great place to work – 21 points higher than the average U.S. company.
MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.
MicroVention, Inc., a subsidiary of Terumo and a global neurovascular company, announced the first U.S. clinical case of its next generation Flow Diverter, the FRED X device, at Thomas Jefferson University Hospital located in Philadelphia.
